NEW YORK, Oct 24 – Genomic Solutions said Tuesday its third quarter losses narrowed significantly, beating Wall Street’s expectations by 5 cents.

The company reported pro forma net losses of $869,000, or 3 cents per share, compared with a net loss of $3.9 million, or $1.31 per share, in the year-earlier period, including a $1.2 million non-cash common stock warrant charge. Excluding that charge, third-quarter 1999 losses were 92 cents per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.